Body mass index and the risk of incident noncommunicable diseases after starting antiretroviral therapy

HIV Medicine

Volumn 16, Issue 1, 2015, Pages 67-72

  Koethe, J R ^a   Jenkins, C A ^a   Turner, M ^a   Bebawy, S ^a   Shepherd, B E ^a   Wester, C W ^a   Sterling, T R ^a  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Antiretroviral therapy; Body mass index; HIV; Non AIDS defining events; Noncommunicable diseases; Nutrition; Obesity

Indexed keywords

ANTIHYPERTENSIVE AGENT; ANTIRETROVIRUS AGENT; HUMAN IMMUNODEFICIENCY VIRUS PROTEINASE INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; ILLICIT DRUG; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT;

ADULT; ALCOHOL CONSUMPTION; ARTICLE; BODY MASS; CANNABIS SMOKING; CARDIOVASCULAR DISEASE; COHORT ANALYSIS; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; KIDNEY DISEASE; LIVER DISEASE; MAJOR CLINICAL STUDY; MALE; MORTALITY; NEOPLASM; NON COMMUNICABLE DISEASE; OBESITY; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SMOKING; SUBSTANCE USE; CHRONIC DISEASE; COMPLICATION; HIV INFECTIONS; IMMUNOLOGY; LONGITUDINAL STUDY; RISK FACTOR;

ADULT; ANTI-HIV AGENTS; BODY MASS INDEX; CHRONIC DISEASE; COHORT STUDIES; FEMALE; HIV INFECTIONS; HUMANS; LONGITUDINAL STUDIES; MALE; OBESITY; OVERWEIGHT; RETROSPECTIVE STUDIES; RISK FACTORS;

EID: 84916244631     PISSN: 14642662     EISSN: 14681293     Source Type: Journal    
DOI: 10.1111/hiv.12178     Document Type: Article

References (20)

1. Crum-Cianflone N, Roediger MP, Eberly L etal. Increasing rates of obesity among HIV-infected persons during the HIV epidemic. PLoS ONE 2010; 5: e10106.
2. Amorosa V, Synnestvedt M, Gross R etal. A tale of 2 epidemics: the intersection between obesity and HIV infection in Philadelphia. J Acquir Immune Defic Syndr 2005; 39: 557-561.
3. Samaras K, Gan SK, Peake PW, Carr A, Campbell LV. Proinflammatory markers, insulin sensitivity, and cardiometabolic risk factors in treated HIV infection. Obesity (Silver Spring) 2009; 17: 53-59.
4. Wand H, Calmy A, Carey DL etal. Metabolic syndrome, cardiovascular disease and type 2 diabetes mellitus after initiation of antiretroviral therapy in HIV infection. AIDS 2007; 21: 2445-2453.
5. Brown TT, Tassiopoulos K, Bosch RJ, Shikuma C, McComsey GA. Association between systemic inflammation and incident diabetes in HIV-infected patients after initiation of antiretroviral therapy. Diabetes Care 2010; 33: 2244-2249.
6. Flegal KM, Kit BK, Orpana H, Graubard BI. Association of all-cause mortality with overweight and obesity using standard body mass index categories: a systematic review and meta-analysis. JAMA 2013; 309: 71-82.
7. McGee DL, Diverse Populations C. Body mass index and mortality: a meta-analysis based on person-level data from twenty-six observational studies. Ann Epidemiol 2005; 15: 87-97.
8. Berrington de Gonzalez A, Hartge P, Cerhan JR etal. Body-mass index and mortality among 1.46 million white adults. N Engl J Med 2010; 363: 2211-2219.
9. Prospective Studies C, Whitlock G, Lewington S etal. Body-mass index and cause-specific mortality in 900000 adults: collaborative analyses of 57 prospective studies. Lancet 2009; 373: 1083-1096.
10. Boggs DA, Rosenberg L, Cozier YC etal. General and abdominal obesity and risk of death among black women. N Engl J Med 2011; 365: 901-908.
11. National Heart Lung and Blood Institute (NHLBI). The evidence report: clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults. Bethesda, MD. NIH Publication No. 98-4083, 1998.
12. Harrell FE. Regression Modeling Strategies with Applications to Linear Models, Logistic Regression, and Survival Analysis. New York, Springer-Verlag, 2001.
13. Samaras K, Wand H, Law M, Emery S, Cooper D, Carr A. Prevalence of metabolic syndrome in HIV-infected patients receiving highly active antiretroviral therapy using International Diabetes Foundation and Adult Treatment Panel III criteria: associations with insulin resistance, disturbed body fat compartmentalization, elevated C-reactive protein, and [corrected] hypoadiponectinemia. Diabetes Care 2007; 30: 113-119.
14. Koethe JR, Dee K, Bian A etal. Circulating interleukin-6, soluble CD14, and other inflammation biomarker levels differ between obese and nonobese HIV-infected adults on antiretroviral therapy. AIDS Res Hum Retroviruses 2013; 29: 1019-1025.
15. Boodram B, Plankey MW, Cox C etal. Prevalence and correlates of elevated body mass index among HIV-positive and HIV-negative women in the Women's Interagency HIV Study. AIDS Patient Care STDS 2009; 23: 1009-1016.
16. Jones CY, Hogan JW, Snyder B etal. Overweight and human immunodeficiency virus (HIV) progression in women: associations HIV disease progression and changes in body mass index in women in the HIV epidemiology research study cohort. Clin Infect Dis 2003; 37 (Suppl 2): S69-S80.
17. Reinsch N, Neuhaus K, Esser S etal. Are HIV patients undertreated? Cardiovascular risk factors in HIV: results of the HIV-HEART study. Eur J Prev Cardiol 2012; 19: 267-274.
18. Lichtenstein KA, Armon C, Buchacz K etal. Provider compliance with guidelines for management of cardiovascular risk in HIV-infected patients. Prev Chronic Dis 2013; 10: E10.
19. Koethe JR, Hulgan T, Niswender K. Adipose tissue and immune Function: a review of evidence relevant to HIV infection. J Infect Dis 2013; 208: 1194-1201.
20. Mulligan K, Harris DR, Monte D etal. Obesity and dyslipidemia in behaviorally HIV-infected young women: adolescent trials network study 021. Clin Infect Dis 2010; 50: 106-114.